In a recent study published in eClinicalMedicine , researchers investigate the weight loss outcomes of semaglutide treatment in obese patients with type 2 diabetes (T2D) based on their individualized metabolic surgery (IMS) score. Study: Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score . Image Credit: Proxima Studio / Shutterstock.
com Obesity, which affects nearly two billion people globally, is closely associated with T2D and other serious comorbidities such as cardiovascular diseases. Despite various interventions like lifestyle changes, medications, and bariatric surgery, managing weight loss remains challenging. Among the different anti-obesity medications approved by the United States Food and Drug Administration (FDA), semaglutide has been shown to support significant weight loss in patients without T2D; however, its effectiveness is reduced in those with the condition.
Although previous studies indicate that certain factors, like insulin use, may influence weight loss outcomes, limited data exist on other parameters that may affect the efficacy of semiglutide treatment. The IMS score, which assesses T2D severity using parameters like glycemic control and insulin use, has been validated for predicting T2D remission post-bariatric surgery. Researchers theorized that patients with severe T2D, as indicated by higher IMS scores, would experience less weight loss with semaglutide treatment.
Thus, the aim of the.
